North America Dominates the Global Osteoporosis Drugs Market
" The global osteoporosis drugs market is expected to witness a CAGR of 4.3% to reach revenue of over $13 billion by 2025 "
Bangalore, India, September 18, 2019: With its recently published study “Global Osteoporosis Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025”, Infoholic Research forecasts that the global osteoporosis drugs market will continue to grow owing to increasing geriatric population, upsurge in the incidence of osteoporosis across the globe, and growing awareness about osteoporotic care. Rising healthcare expenditure in the developing countries and increased approval of new drugs and pipeline products are projected to support the market growth during the forecast period 2019–2025.
The osteoporosis drugs market by drug class is segmented into bisphosphonates, parathyroid hormone therapy, selective estrogen receptor modulator, RANK ligand inhibitors, biosimilars, and others. Among these, bisphosphonates occupied a dominant share in 2018 and biosimilars is expected to grow at a high CAGR during the forecast period 2019–2025. Increased preference of bisphosphonates by physicians for the treatment and prevention makes the segment as the largest share holder in 2018.
Get a sample copy of the report @ https://www.infoholicresearch.com/request-a-sample-report/?repid=14474
The patents of bestseller osteoporosis drugs is going to expire, which will pave a way for the emergence of biosimilars. For instance, the patent of Amgen’s Prolia (Denosumab) will expire in the US in 2025 and in Europe in 2022. Currently there are five drug companies conducting ongoing clinical development of Denosumab biosimilar. Intas pharmaceuticals and AryoGen Pharmed are in advanced phase III clinical trial, whereas other two companies are in preclinical and pipeline phase.
Many companies are investing highly in developing new products to enter the market. For instance, in August 2019, STADA announced the launch of Teriparatide biosimilar, Movymia for the treatment of osteoporosis by launching in 24 countries.
Access Full Report Summary @ https://www.infoholicresearch.com/report/osteoporosis-drugs-market/
The global osteoporosis drugs market is segmented in the regions of North America, Europe, Asia Pacific, and Rest of the World. North America occupied a significant market share in 2018 and Asia Pacific is likely to grow at a high CAGR during the forecast period. The presence of established medical and healthcare infrastructure, existence of reputed players extensively involved in the commercialization of branded therapeutics, and increasing patient base for osteoporosis make North America a dominant shareholder in the global osteoporosis drugs market. Increasing occurrence of the disease, rising disposable income, growing healthcare awareness, and consistent investment in R&D have made Asia Pacific the fastest-growing region in the global osteoporosis drugs market.
“The osteoporosis drugs market is growing at low single digit CAGR and key vendors are focusing on product approvals and R&D of new products to increase their share in the market. The focus has turned from the manufacturing of antiresorptive agents to anabolic agents, and anabolics will be preferred product of choice for the upcoming market players. In addition growing focus on the development of effective drug delivery system will augment the growth of the market in the coming years." – Arpitha Shetty, Research Analyst, Infoholic Research
Key Insights of the Report Include:
- By Drug Class:
- Parathyroid Hormone Therapy
- Selective Estrogen Receptor Modulator
- RANK Ligand Inhibitors
- By Regions:
- North America
- Asia Pacific
- Rest of the World
- Industry Outlook: Market trends, drivers, restraints, and opportunities